Use of tigecycline in pediatric clinical practice

ABSTRACT Introduction: Tigecycline, a derivative of minocycline, is an extended-spectrum antimicrobial agent. It has a restricted approval field in children and the experience of its adoption in clinical practice is reserved for cases of challenging infections. The aim of this review was to summarize evidence regarding the use of tigecycline in infants and children, focusing on the drug’s clinical efficacy data and tolerability profile. Areas covered: We have conducted a literature search of the Cochrane Library, EMBASE, and MEDLINE databases, from their inception through 5 January 2017, using the following terms: tigecycline, newborn, infant, child, pediatrics, adolescent, human, clinical trial, and case report. Articles were excluded if they were redundant or not pertinent. Bibliographies of all relevant articles were also evaluated. Seventeen publications were included: 1 pharmacokinetic study, 16 case reports. In the selected publications, the patients’ mean age was 4.45 years, 38.7% of children was <3 years old and favorable clinical response was achieved in 74.2% of cases. Expert commentary: Tigecycline may be a considerable option in life-threatening infections in pediatric patients. Its administration is well tolerated and has demonstrated a good clinical response in nonbacteremic patients. However, the available clinical records are limited and more studies are needed.

[1]  Hatice Turk Dagi,et al.  Tigecycline Therapy in an Infant for Ventriculoperitoneal Shunt Meningitis , 2017, Pediatrics.

[2]  E. Roilides,et al.  Use of Tigecycline in Pediatric Patients With Infections Predominantly Due to Extensively Drug-Resistant Gram-Negative Bacteria , 2016, Journal of the Pediatric Infectious Diseases Society.

[3]  W. Ye,et al.  Retrospective analysis of tigecycline shows that it may be an option for children with severe infections , 2016, Acta paediatrica.

[4]  S. Esposito,et al.  Carbapenem-resistant Enterobacteriaceae Infections in Children: An Italian Retrospective Multicenter Study , 2016, The Pediatric infectious disease journal.

[5]  Kuo-Feng Huang,et al.  Tigecycline salvage therapy for necrotizing fasciitis caused by Vibrio vulnificus: Case report in a child. , 2016, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[6]  A. Gori,et al.  Tigecycline Lock Therapy for Catheter-Related Bloodstream Infection Caused by KPC-Producing Klebsiella pneumoniae in Two Pediatric Hematological Patients , 2015, Antimicrobial Agents and Chemotherapy.

[7]  A. Kara,et al.  Multidrug-resistant Acinetobacter baumannii bacteremia treated with tigecycline in two pediatric burn patients. , 2015, The Pediatric infectious disease journal.

[8]  I. Vijayalakshmi,et al.  Purulent Pericarditis with Quadruple Valve Endocarditis , 2015, The American journal of case reports.

[9]  D. Tuğcu,et al.  Successful treatment of multiresistant Achromobacter xylosoxidans bacteremia in a child with acute myeloid leukemia , 2015, Annals of Saudi medicine.

[10]  S. Kehl,et al.  Global Assessment of Antimicrobial Susceptibility among Gram-Negative Organisms Collected from Pediatric Patients between 2004 and 2012: Results from the Tigecycline Evaluation and Surveillance Trial , 2015, Journal of Clinical Microbiology.

[11]  P. Smith,et al.  Pharmacokinetics and safety of recently approved drugs used to treat methicillin-resistant Staphylococcus aureus infections in infants, children and adults , 2014, Expert review of clinical pharmacology.

[12]  F. Tenover,et al.  A pediatric case of New Delhi metallo-β-lactamase-1-producing Enterobacteriaceae in the United States. , 2013, The Pediatric infectious disease journal.

[13]  Yunsong Yu,et al.  Tigecycline treatment of infection caused by KPC-producing Escherichia coli in a pediatric patient , 2013, Annals of Clinical Microbiology and Antimicrobials.

[14]  M. Dowzicky,et al.  Antimicrobial Susceptibility among Gram-Positive Organisms Collected from Pediatric Patients Globally between 2004 and 2011: Results from the Tigecycline Evaluation and Surveillance Trial , 2013, Journal of Clinical Microbiology.

[15]  D. Zanon,et al.  Neutrophils Engraftment Delay During Tigecycline Treatment in 2 Bone Marrow–transplanted Patients , 2013, Journal of pediatric hematology/oncology.

[16]  A. Restrepo,et al.  [Experience with tigecycline compassionate use in pediatric patients infected with carbapenem resistant Klebsiella pneumoniae]. , 2012, Revista chilena de infectologia : organo oficial de la Sociedad Chilena de Infectologia.

[17]  J. Korth-Bradley,et al.  Pharmacokinetics and safety profile of tigecycline in children aged 8 to 11 years with selected serious infections: a multicenter, open-label, ascending-dose study. , 2012, Clinical therapeutics.

[18]  P. Palma,et al.  Multidrug-resistant Acinetobacter baumannii infection in children , 2011, BMJ Case Reports.

[19]  R. Basmaci,et al.  Pediatric acute pancreatitis related to tigecycline. , 2010, The Pediatric infectious disease journal.

[20]  A. Kiremitçi,et al.  Tigecycline treatment of multi‐drug‐resistant Corynebacterium jeikeium infection in a child with relapsing and refractory acute lymphoblastic leukemia , 2010, Pediatric Blood & Cancer.

[21]  S. Browd,et al.  Multidrug-resistant Enterococcus faecium meningitis in a toddler: characterization of the organism and successful treatment with intraventricular daptomycin and intravenous tigecycline. , 2009, The Pediatric infectious disease journal.

[22]  A. E. El Solh,et al.  Tigecycline attenuates staphylococcal superantigen-induced T-cell proliferation and production of cytokines and chemokines , 2009, Immunopharmacology and immunotoxicology.

[23]  L. Peterson.  A review of tigecycline--the first glycylcycline. , 2008, International journal of antimicrobial agents.

[24]  B. Cirincione,et al.  Exposure-Response Analyses of Tigecycline Efficacy in Patients with Complicated Skin and Skin-Structure Infections , 2007, Antimicrobial Agents and Chemotherapy.

[25]  R. Steele,et al.  Tigecycline: A Single Antibiotic for Polymicrobial Infections , 2007, The Pediatric infectious disease journal.

[26]  H. B. Fung,et al.  Tigecycline: a glycylcycline antimicrobial agent. , 2006, Clinical therapeutics.

[27]  J. Rello.  Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Tigecycline , 2005, Journal of chemotherapy.

[28]  P. Bradford,et al.  A Novel MATE Family Efflux Pump Contributes to the Reduced Susceptibility of Laboratory-Derived Staphylococcus aureus Mutants to Tigecycline , 2005, Antimicrobial Agents and Chemotherapy.

[29]  E. Rubinstein,et al.  Tigecycline , 2012, Drugs.

[30]  C. Dean,et al.  Efflux-Mediated Resistance to Tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1 , 2003, Antimicrobial Agents and Chemotherapy.

[31]  M. Ammirati,et al.  Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-mediated ribosomal protection , 1996, Antimicrobial agents and chemotherapy.